Expertise in
5
conditions

Mark K. Doherty

Toronto, ON, CA 
Expertise in
5
conditions
Toronto, ON, CA 

Overview

Mark Doherty practices practicing medicine in Toronto, Canada.

Mr. Doherty is highly rated in 5 conditions, according to our data. His clinical expertise encompasses Cholangiocarcinoma (Bile Duct Cancer), Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), and ALK-Positive Non-Small Cell Lung Cancer.

He is actively involved in clinical research, co-authoring 45 peer reviewed articles and participating in 2 clinical trials.

Gender

Male

Locations

Toronto, ON, Canada
Other Locations
On, Canada

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Multi-Centre, Open-Label Phase 2 Study of TRIFLURIDINE/TIPIRACIL in Previously Treated Cholangiocarcinoma (The MOCHA Trial)
A Multi-Centre, Open-Label Phase 2 Study of TRIFLURIDINE/TIPIRACIL in Previously Treated Cholangiocarcinoma (The MOCHA Trial)
Enrollment Status: Terminated
Publish Date: December 01, 2022
Intervention Type: Drug
Study Drug: Trifluridine
Study Phase: Phase 2
A Phase 2, Open-label, Multicenter, Study of an Immunotherapeutic Treatment, DPX-Survivac in Combination With Low Dose Cyclophosphamide and Pembrolizumab, in Subjects With Selected Advanced and Recurrent Solid Tumours.
A Phase 2, Open-label, Multicenter, Study of an Immunotherapeutic Treatment, DPX-Survivac in Combination With Low Dose Cyclophosphamide and Pembrolizumab, in Subjects With Selected Advanced and Recurrent Solid Tumours.
Enrollment Status: Active_not_recruiting
Publish Date: March 31, 2022
Intervention Type: Other, Drug
Study Drugs: Cyclophosphamide, Pembrolizumab
Study Phase: Phase 2
View 1 Less Clinical Trial

45 Total Publications

Osimertinib and Stereotactic Radiosurgery for Brain Metastases in EGFR-Mutated Lung Cancer: The STARLET Joint Analysis of OUTRUN and LUOSICNS Randomized Trials.
Osimertinib and Stereotactic Radiosurgery for Brain Metastases in EGFR-Mutated Lung Cancer: The STARLET Joint Analysis of OUTRUN and LUOSICNS Randomized Trials.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: October 17, 2025

Frequently Asked Questions about Mark K. Doherty

Is Mark K. Doherty a top-rated expert for Cholangiocarcinoma (Bile Duct Cancer)?

MediFind is an objective health platform that identifies experts based on real-world data. Mark K. Doherty is classified as an Advanced expert for Cholangiocarcinoma (Bile Duct Cancer), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Mark K. Doherty participate in research or clinical trials?

Yes. Mark K. Doherty has published 45 articles and abstracts on conditions like Cholangiocarcinoma (Bile Duct Cancer). You can view a list of Mark K. Doherty's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Doherty's expertise for a condition
ConditionClose
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile